O
Osvaldo Regueira
Researcher at Texas Tech University Health Sciences Center
Publications - 5
Citations - 147
Osvaldo Regueira is an academic researcher from Texas Tech University Health Sciences Center. The author has contributed to research in topics: Nephrotoxicity & Ifosfamide. The author has an hindex of 4, co-authored 5 publications receiving 127 citations. Previous affiliations of Osvaldo Regueira include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Treatment of juvenile xanthogranuloma.
TL;DR: A literature review of multisystem JXG cases treated with chemotherapy suggests that symptomatic patients can successfully be treated with LCH‐based regimens that include both corticosteroids and vinca alkaloids.
Journal ArticleDOI
N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics.
Lauren Hanly,Nancy Chen,Katarina Aleksa,Katarina Aleksa,Murray J. Cutler,Murray J. Cutler,Milica Bajcetic,Milica Bajcetic,Rasmi Palassery,Osvaldo Regueira,Curtis Turner,Bandar Baw,Becky Malkin,David J. Freeman,David J. Freeman,Michael J. Rieder,Tetyana L. Vasylyeva,Gideon Koren +17 more
TL;DR: NAC's potential to protect against IFO‐induced nephrotoxicity in children when used in its clinically approved dose schedule is corroborate and supports a clinical trial in children.
Journal Article
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
Lauren Hanly,Michael J. Rieder,Shih-Han S Huang,Tetyana L. Vasylyeva,Rikin K. Shah,Osvaldo Regueira,Gideon Koren +6 more
TL;DR: N-acetylcysteine has successfully protected against ifosfamide-induced nephrotoxicity in both cell and rodent models, as well as in several paediatric cases, suggesting it should be evaluated as a treatment option for children on ifosFamide who present with renal dysfunction.
Journal ArticleDOI
N-acetylcysteine renoprotection in methotrexate induced nephrotoxicity and its effects on B-cell lymphoma
TL;DR: Using NAC for kidney protection may not interfere with the antitumor activity of MTX, and in vivo studies are warranted to confirm noninterference between MTX and NAC and assess synergistic antitumors effects.